https://ph-ksp.com/initial-triple-combination-therapy-including-sotatercept-in-a-patient-with-severe-idiopathic-pulmonary-arterial-hypertension-ipah-a-case-report-erj-open-research-march-30-2026/ 2026-04-01T17:34:15Z PULMONARY HYPERTENSION en A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026 2026-04-01T17:33:14Z Blog https://ph-ksp.com/detecting-pulmonary-hypertension-earlier-us-food-and-drug-administration-fda-clears-anumanas-ai-echocardiogram-algorithm/ 2026-04-01T07:11:05Z PULMONARY HYPERTENSION en Detecting pulmonary hypertension earlier? US Food and Drug Administration (FDA) clears Anumana's AI echocardiogram algorithm 2026-04-01T06:58:40Z Blog https://ph-ksp.com/promising-results-for-nebulised-treprostinil-tyvaso-in-treating-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-who-group-3/ 2026-04-01T06:36:49Z PULMONARY HYPERTENSION en Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3 2026-04-01T06:36:48Z Blog https://ph-ksp.com/sotatercept-for-who-group-2-pulmonary-hypertension-sub-group-results-from-the-phase-2-randomized-placebo-controlled-cadence-study-circulation-march-29-2026/ 2026-04-01T06:23:28Z PULMONARY HYPERTENSION en Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026 2026-04-01T06:23:26Z Blog